(PIII) P3 Health Partners - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7444131053
PIII: Healthcare, Clinics, Wellness, Population, Management
P3 Health Partners Inc. (NASDAQ:PIII) is a patient-centered and physician-led population health management company specializing in value-based care services across the United States. Founded in 2020 and headquartered in Henderson, Nevada, the company operates a network of clinics and wellness centers designed to deliver integrated healthcare solutions. P3 Health Partners focuses on improving health outcomes through preventive care, chronic disease management, and coordinated medical services. The company has expanded its footprint rapidly since its inception, emphasizing a data-driven approach to population health management.
From a technical perspective, PIII has shown declining momentum, with its SMA 20 and SMA 50 trending below the SMA 200, indicating bearish sentiment. The stocks average trading volume of 1.24 million shares over 20 days suggests moderate liquidity. The ATR of 0.02 reflects low volatility, while the last price of $0.18 is below its short-term moving averages, signaling potential weakness. Fundamental analysis reveals a market cap of $104.97 million, with a price-to-book ratio of 0.25, indicating undervaluation relative to book value. However, the negative return on equity (-85.21%) and lack of forward P/E suggest significant financial challenges.
3-Month Forecast: - Technical Outlook: - The stock is likely to remain under pressure, with potential resistance at $0.21 (SMA 50) and support at $0.15. - Expect continued range-bound trading with limited upside due to the bearish crossover of SMA 20 below SMA 50. - Fundamental Outlook: - P3 Health Partners may face operational headwinds due to its negative return on equity and lack of profitability. - The companys valuation multiples, such as P/S of 0.07, suggest limited upside unless it demonstrates significant revenue growth or margin improvement.Additional Sources for PIII Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PIII Stock Overview
Market Cap in USD | 3,651m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2021-04-06 |
PIII Stock Ratings
Growth Rating | -85.0 |
Fundamental | -1.46 |
Dividend Rating | 0.0 |
Rel. Strength | -62.9 |
Analysts | 4/5 |
Fair Price Momentum | 3.86 USD |
Fair Price DCF | - |
PIII Dividends
No Dividends PaidPIII Growth Ratios
Growth Correlation 3m | -56.1% |
Growth Correlation 12m | -93.9% |
Growth Correlation 5y | -95.9% |
CAGR 5y | -62.71% |
CAGR/Max DD 5y | -0.64 |
Sharpe Ratio 12m | -1.39 |
Alpha | -71.67 |
Beta | 0.826 |
Volatility | 98.44% |
Current Volume | 9.6k |
Average Volume 20d | 9.1k |
As of April 30, 2025, the stock is trading at USD 8.75 with a total of 9,560 shares traded.
Over the past week, the price has changed by -1.57%, over one month by +6.64%, over three months by -9.04% and over the past year by -62.63%.
Neither. Based on ValueRay Fundamental Analyses, P3 Health Partners is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -1.46 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PIII as of April 2025 is 3.86. This means that PIII is currently overvalued and has a potential downside of -55.89%.
P3 Health Partners has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy PIII.
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PIII P3 Health Partners will be worth about 4.3 in April 2026. The stock is currently trading at 8.75. This means that the stock has a potential downside of -50.74%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 31.3 | 257.1% |
Analysts Target Price | 31.3 | 257.1% |
ValueRay Target Price | 4.3 | -50.7% |